---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dosage forms and strengths"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dosage forms and strengths. Topics: Investigational dosage form: 45 mg film-coated tablet for oral use, Tablets in the AMPLITUDE and AMPLIFIED trials, Pediatric acceptability of the tablet formulation, and Tablet formulation development: relative bioavailability and food effect study. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Investigational dosage form: 45 mg film-coated tablet for oral use

| Field | Quoted record |
| --- | --- |
| Product | “VX-147 film-coated tablet” |
| Pharmaceutical form | “FILM-COATED TABLET” |
| Route of administration | “ORAL USE” |
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |
| Placebo | “VX-147, Coated Placebo Tablet” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

> “Inaxaplin is being evaluated as a 45 mg once-daily oral dose compared to placebo, on top of standard of care.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.1.2.2-2"></a>

### Tablets in the AMPLITUDE and AMPLIFIED trials

> “Drug: VX-147 Tablets for oral administration.”
> “Drug: Placebo Tablets for oral administration.”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

> “Drug: Inaxaplin Tablets for Oral Administration.”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-2.1.2.2-3"></a>

### Pediatric acceptability of the tablet formulation

> “Part A: Acceptability Tablet Formulation of VX-147 in Pediatric Participants using the Convenience Domain of the Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-2.1.2.2-4"></a>

### Tablet formulation development: relative bioavailability and food effect study

> “The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="topic-2.1.2.2-5"></a>

### Commercial strengths and package sizes

No evidence found.

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
